Gilead's John C. Martin, PhD to Assume Role of Executive Chairman of the Board; John F. Milligan, PhD to Be Appointed Chief Executive Officer and Director

FOSTER CITY, Calif.--()--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that, effective March 10, 2016, current Chairman and CEO John C. Martin, PhD will assume the role of Executive Chairman of the company. John F. Milligan, PhD, currently President and Chief Operating Officer, will be promoted to CEO and appointed to the company's Board of Directors.

John Martin joined Gilead in 1990 and was appointed Chief Executive Officer in 1996 and Chairman of the Board in 2008. John Milligan also joined Gilead in 1990 and was appointed Chief Operating Officer in 2007 and President in 2008.

"John Martin has led Gilead as CEO for the past 20 years, and under his stewardship, the company has developed and delivered therapeutic advancements to millions of people around the world. His legacy is clear – and the vision he has set will continue with his contributions as Executive Chairman," said John Cogan, PhD, Gilead's Lead Independent Director.

"Over the past 25 years, John Milligan has distinguished himself as an exceptional leader, serving in diverse management roles and overseeing multiple phases of growth and expansion into new therapeutic areas and geographies. The Board of Directors and I are confident in his ability to lead Gilead into the future," commented John Martin.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

Forward-Looking Statement

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statement.

For more information on Gilead Sciences, please visit the company's website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

 

Contacts

Gilead Sciences, Inc.
Investors
Patrick O'Brien, 650-522-1936
or
Media
Amy Flood, 650-522-5643